SCHEMBL29544673

SCHEMBL29544673

COc1ccc(-c2ccon2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
CYP19A1 P11511 3/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
CYP2A6 P11509 2/20 0.46
P2RX3 P56373 2/20 0.45
FYN P06241 2/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
NNMT P40261 1/20 0.41
ERN1 O75460 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174412 0.77 CYP2A6 (0.68) CYP19A1MKNK1MKNK2CYP2A6FYN
SCHEMBL3754419 0.77 CYP2A6 (0.68) CYP19A1MKNK1MKNK2CYP2A6FYN
SCHEMBL2726056 0.77 CYP1A2 (0.47) NPC1RAB9ACYP19A1CYP1A2CYP2D6
SCHEMBL4317162 0.76 MKNK1 (0.47) CYP19A1MKNK1MKNK2CYP2A6FYN
SCHEMBL24921545 0.76 MKNK1 (0.47) CYP19A1MKNK1MKNK2CYP2A6FYN
SCHEMBL17644086 0.74 NPC1 (0.72) NPC1RAB9ACYP19A1CYP1A2CYP2D6
SCHEMBL30685984 0.73 KCNH2 (0.47) NPC1RAB9ACYP19A1MKNK1MKNK2
SCHEMBL30473743 0.73 PIK3CD (0.46) NPC1RAB9ACYP19A1MKNK1MKNK2
SCHEMBL25344353 0.73 PIK3CD (0.46) NPC1RAB9ACYP19A1MKNK1MKNK2
SCHEMBL2844671 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2022-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER KIT, TNNI3K, CILK1 NPC1 2038/4885RAB9A 2229/4885CYP19A1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.